HospitalNews

ACC performs India’s first robotic CRS with Hyperthermic Intraperitoneal Chemotherapy for peritoneal surface cancer

The invasive, robotic-assisted approach marks a paradigm shift in treating Pseudomyxoma Peritonei (PMP), an aggressive appendix cancer, offering patients a new standard of care, enabling faster recovery and improved quality of life

Apollo Cancer Centre (ACC) has successfully performed India’s first Robotic Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for peritoneal surface cancer. This minimally invasive, robotic-assisted approach marks a paradigm shift in treating Pseudomyxoma Peritonei (PMP), an aggressive appendix cancer, offering patients a new standard of care, enabling faster recovery and improved quality of life.

Dr Ajit Pai, Senior Consultant in Surgical Oncology and Robotic Surgery, Apollo Cancer Centre, Chennai along with his team, spearheaded this first-of-its-kind approach. The collaborative clinical expertise and unwavering dedication to transformative tech innovations at ACC were instrumental in achieving this remarkable success.

Dr Pai, said, “Robotic CRS offers a transformative approach, requiring expertise in traditional and robotic techniques for precise tumour resections. With reduced post-operative morbidity, minimal access, and quicker recovery, this method is a viable choice for patients whose cancer cells have spread to and implanted on the peritoneal surfaces in a limited manner. We are thrilled with the successful clinical   outcome and the potential this approach holds for improving the lives of patients battling peritoneal surface cancers, including those from ovarian, colonic and gastric malignancies.” 

Dr Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Enterprises Ltd, said, ” At ACC, we understand that cutting-edge technology is just one piece of the puzzle. While we invest in the most advanced technologies available, it’s our exceptional team of clinicians who truly unlock the potential of unparalleled clinical excellence. This powerful synergy between technology, innovation and clinical expertise sets Apollo apart, enabling millions across the world to Win Over Cancer.” 

Dinesh Madhavan, President Group Oncology and International, Apollo Hospitals Enterprises, said, “Robotics is revolutionising cancer care, offering unparalleled precision and minimal invasiveness. At ACC, we leverage this technology to enhance treatment outcomes, reduce recovery times, and provide our patients with the most advanced therapies available todayThis is India’s first novel approach (robotic CRS and HIPEC) by our exceptional clinical team for treating peritoneal surface cancers is yet another testament to our unwavering commitment to providing patients with the best-in-class treatment.” 

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
IndiaMedToday
Close
Close